Brief: Everest Medicines Says Sacituzumab Govitecan-Hziy Granted Priority Review
20/05/2021 16:09
May 20 (Reuters) - Everest Medicines Ltd 1952.HK :
* SACITUZUMAB GOVITECAN-HZIY GRANTED PRIORITY REVIEW BY
CENTER FOR
DRUG EVALUATION OF CHINA NMPA
Source text for Eikon: ID:nHKS1NsLm9
Further company coverage: 1952.HK
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region